SOHO State of the Art Updates and Next Questions-WHO Classification of Acute Myeloid Leukemia.

[1]  G. Toruner,et al.  Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma. , 2024, American journal of hematology.

[2]  G. Göhring,et al.  Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia , 2023, Leukemia.

[3]  S. Zeger,et al.  DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. , 2023, JAMA.

[4]  G. Garcia-Manero,et al.  Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements , 2023, American journal of hematology.

[5]  S. Mustjoki,et al.  Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia , 2022, Blood.

[6]  B. Ebert,et al.  Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.

[7]  M. Loh,et al.  International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.

[8]  Y. Natkunam,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.

[9]  K. Döhner,et al.  2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. , 2021, Blood.

[10]  Dao-bin Zhou,et al.  Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia. , 2021, American journal of clinical pathology.

[11]  S. Armstrong,et al.  The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML , 2021, Blood.

[12]  J. Kanda,et al.  Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia , 2021, Blood advances.

[13]  H. Einsele,et al.  CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome. , 2021, Blood.

[14]  R. Ries,et al.  CEBPA bZip Mutations are Associated with Favorable Prognosis in de novo AML: A Report from the Children's Oncology Group. , 2021, Blood.

[15]  M. Konopleva,et al.  Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia , 2021, British journal of haematology.

[16]  Austin E. Gillen,et al.  Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. , 2020, Cancer discovery.

[17]  W. Wong,et al.  Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. , 2019, Blood advances.

[18]  M. Konopleva,et al.  NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. , 2019, Blood advances.

[19]  A. Chiu,et al.  De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity , 2018, Modern Pathology.

[20]  M. Konopleva,et al.  More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. , 2017, Blood.

[21]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[22]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[23]  H. Kestler,et al.  RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features , 2016, Leukemia.

[24]  J. Qian,et al.  CEBPA methylation and mutation in myelodysplastic syndrome , 2015, Medical Oncology.

[25]  J. Merker,et al.  Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations , 2015, Modern Pathology.

[26]  D. Birnbaum,et al.  Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes , 2015, Oncotarget.

[27]  D. Neuberg,et al.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.

[28]  P. Aplan,et al.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. , 2011, Blood.

[29]  L. Medeiros,et al.  Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. , 2011, American journal of clinical pathology.

[30]  L. Medeiros,et al.  Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification , 2011, Modern Pathology.

[31]  P. Rothberg,et al.  Is the association of "cup-like" nuclei with mutation of the NPM1 gene in acute myeloid leukemia clinically useful? , 2010, American journal of clinical pathology.

[32]  Paola Fazi,et al.  Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). , 2010, Blood.

[33]  S. Pileri,et al.  Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help , 2010, Haematologica.

[34]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.